NAGE
Niagen Bioscience, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Niagen Bioscience, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Last report1 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Mar 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Niagen Bioscience, Inc.
2.53
+0.17 · +7.20%
post 2.37 −6.32%
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $13.3M | 13.03% | +8.09% |
| Steel Peak Wealth | $11.2M | 10.90% | +3.77% |
| Vanguardindex-like | $6.8M | 6.69% | −0.11% |
| Tieton | $6.4M | 6.26% | −1.02% |
| Qube Research & Technologies | $5.2M | 5.06% | −5.23% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $13.3M | 13.03% | +8.09% |
| Steel Peak Wealth | $11.2M | 10.90% | +3.77% |
| Vanguardindex-like | $6.8M | 6.69% | −0.11% |
| Tieton | $6.4M | 6.26% | −1.02% |
| Qube Research & Technologies | $5.2M | 5.06% | −5.23% |
Same SIC code · 6
Same SEC industry code: Definium Therapeutics, Inc., Usana Health Sciences Inc, MediWound Ltd. and 3 more; of Niagen Bioscience, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Definium Therapeutics, Inc., Usana Health Sciences Inc, MediWound Ltd. and 3 more; of Niagen Bioscience, Inc.'s 6 closest co-movers, none share that code.
Expected move
No implied move.